Q2053 Brexucabtagene autoleucel - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Brexucabtagene autoleucel

Brand Name:

Tecartus

Strength:

2000000

HCPCS:

Q2053

SEER*Rx Category:

Immunotherapy

Major Drug Class:

CAR-T

Minor Drug Class:

CD-19

Oral (Y/N):

No

FDA Approval Year:

2020

FDA Discontinuation Year:

CMS Effective Date:

April 1, 2021

CMS Discontinuation Date:

Status:

In Use